🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Erika J. Lampert

Magee-Womens Hospital

ORCID: 0000-0001-9406-5371

MedicineBiochemistry, Genetics and Molecular BiologyEngineering

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer”.

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer

Science Translational Medicine(2023)10.1126/scitranslmed.add7872

N/A

0.790DataRank · unranked

25 citations

Tzu‐Ting Huang, Jayakumar R. Nair, Daniel An, Grant Zurcher, Erika J. Lampert +12 more

Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer

Cancer Treatment Reviews(2020)10.1016/j.ctrv.2020.102021

N/A

0.770DataRank · unranked

169 citations

Erika J. Lampert, Cynthia Coots, Jungmin Lee, Tzu‐Ting Huang

Prexasertib, a cell cycle checkpoint kinase 1 inhibitor, in BRCA mutant recurrent high-grade serous ovarian cancer (HGSOC): A proof-of-concept single arm phase II study.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.6038

N/A

0.312DataRank · unranked

7 citations

Daniel An, Ann McCoy, Elise C. Kohn, Christina M. Annunziata, Kathryn Trewhitt +4 more

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0056

N/A

0DataRank · unranked

224 citations

Alexandra S. Zimmer, Michelle R. Padget, Ashley Cimino‐Mathews, Jayakumar R. Nair, Yingmiao Liu +13 more

Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000516

N/A

0DataRank · unranked

27 citations

Ashley Cimino‐Mathews, Joo Sang Lee, Jayakumar R. Nair, Min-Jung Lee, Akira Yuno +5 more

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA-mutant ovarian cancer

medRxiv(2022)10.1101/2022.12.02.22283037

N/A

0DataRank · unranked

2 citations

Tzu‐Ting Huang, Jayakumar R. Nair, Daniel An, Grant Zurcher, Erika J. Lampert +12 more